去纤维钠（去纤苷）国内买的到吗？

(Defibroside) is currently recognized as the most promising new drug for the treatment of HVOD after HSCT. Based on its anticoagulant, fibrinolysis-promoting, and anti-inflammatory effects, foreign researchers have explored its application in the treatment of HVOD after HSCT. This study included 19 sHVOD patients. The dose of defibrotide is 5 to 60 mg/kg per day, intravenous infusion, and the median use time is 15 days (2 to 61 days). The results showed that 42% of patients achieved complete remission (CR), and the overall survival (OS) rate 100 days after transplantation reached 32%, and patients could tolerate defibrotide well.

Defibrotide sodium was officially approved by the FDA at the end of March 2016, providing another new treatment option and opportunity for many patients. Many patients must have asked: Is defibrotide sodium (defibrinoside) available in China?

The answer is that you can't buy it. Because defibrotide sodium has not yet been approved for marketing in China, patients who need this drug can only choose to purchase defibrotide which is sold overseas. The process of purchasing abroad is complicated, and it also faces language barriers and other problems, which is time-consuming, laborious and expensive.

In this regard, patients can contact domestic overseas medical service institutions (such as Medical Companion Travel) to obtain drug purchase channels for Defitelio. Through this method, patients can effectively avoid problems such as being unable to distinguish the authenticity of drugs, high round-trip costs, and complicated procedures. At the same time, patients can also more conveniently obtain the safe and good drugs they need.

Patients should not experience clinically significant bleeding and be hemodynamically stable with no more than one vasopressin prior to administration of defibrotide sodium. Administer by constant intravenous infusion over a 2-hour period, flushing the intravenous administration line (peripheral or central) with 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, before and immediately after administration.

Recommended hot articles: /newsDetail/78605.html